An integrated multi‐omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid
Cancer Cytopathology · 2025
DOI: 10.1002/cncy.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2025. Verfasst von Mohamed H Maher und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Laboratory Medicine, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Ho…. Hauptthemen laut MEDLINE: Pancreatic Cyst, MicroRNAs, Biomarkers, Tumor, Cyst Fluid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Classification and risk stratification of pancreatic cysts are challenging because of limited radiographic and cytomorphologic features. Although molecular profiling has emerged as an ancillary test for pancreatic cyst fluid (PCF), additional high‐sensitivity and ‐specificity biomarkers are still needed for improved classification.
Methods
In this study, PCF from 93 patients, including intraductal papillary mucinous neoplasms ( n = 65), mucinous cystic neoplasms ( n = 9), serous cystadenomas ( n = 9), pancreatic cyst not otherwise specified ( n = 8), and pseudocysts ( n = 2), were evaluated for biomarkers. Molecular profiling by next‐generation sequencing was performed, and a subset of the cases ( n = 32) were interrogated with 2083 microRNAs (miRNAs) to evaluate their use for pancreatic cyst risk stratification.
Results
As independent PCF biomarkers in 32 cases with histologic diagnoses, three miRNAs performed significantly better than mutant KRAS , mutant GNAS , carcinoembryonic antigen (CEA), and serum carbohydrate antigen 19‐9 (CA19‐9) in discriminating high‐risk from low‐risk cysts. The three elevated miRNAs in combination with mutant KRAS , mutant GNAS , and serum CA19‐9 displayed similar diagnostic performance (miR‐4461: area under the curve [AUC], 0.950; 95% confidence interval [CI], 0.800–1; miR‐6723‐5p: AUC, 0.958; 95% CI, 0.850–1; miR‐6755‐3p: AUC, 0.942; 95% CI, 0.816–1) in discriminating high‐risk from low‐risk cysts, when compared to mutant KRAS , mutant GNAS , CEA, and serum CA19‐9 (AUC, 0.950; 95% CI, 0.825–1). In the absence of CA19‐9, the three‐marker panel of KRAS , GNAS , and miRNAs showed marginally improved performance compared with KRAS , GNAS , and CEA, which highlights the potential utility of miRNAs as biomarkers in PCF analysis.
Conclusions
These findings demonstrate that a multiomics biomarker approach with elevated PCF miRNAs with mutant KRAS , mutant GNAS , and serum CA19‐9 may help in better detecting high‐risk cysts for early clinical intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pathology and Laboratory Medicine, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
- Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Center for Cellular and Molecular Diagnostics, Department of Cell and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
ORCID-Profile: Mohamed H Maher, Warapen Treekitkarnmongkol, Sayak Ghatak, Jianliang Dai, Suyu Liu, Tristian Nguyen, Dzifa Y Duose, Michael P Kim, Tony Y Hu, Mark W Hurd, Pamela L Paris, Kimberly S Kirkwood, Anirban Maitra, Rajyalakshmi Luthra, Subrata Sen, Sinchita Roy-Chowdhuri
Förderung
- NCI NIH HHS
Zitieren
APA
Maher, M. H., Treekitkarnmongkol, W., Ghatak, S., Dai, J., Liu, S., Nguyen, T., Duose, D. Y., Kim, M. P., Hu, T. Y., Hurd, M. W., Paris, P. L., Kirkwood, K. S., Maitra, A., Luthra, R., Sen, S., & Roy-Chowdhuri, S. (2025). An integrated multi‐omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid. Cancer Cytopathology. https://doi.org/10.1002/cncy.70008
Vancouver
Maher MH, Treekitkarnmongkol W, Ghatak S, Dai J, Liu S, Nguyen T, et al. An integrated multi‐omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid. Cancer Cytopathology. 2025. doi:10.1002/cncy.70008
BibTeX
@article{Maher2025,
author = {Maher, Mohamed H and Treekitkarnmongkol, Warapen and Ghatak, Sayak and Dai, Jianliang and Liu, Suyu and Nguyen, Tristian and Duose, Dzifa Y and Kim, Michael P and Hu, Tony Y and Hurd, Mark W and Paris, Pamela L and Kirkwood, Kimberly S and Maitra, Anirban and Luthra, Rajyalakshmi and Sen, Subrata and Roy-Chowdhuri, Sinchita},
title = {An integrated multi‐omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid},
journal = {Cancer Cytopathology},
year = {2025},
doi = {10.1002/cncy.70008}
}
EUVIMED